Work

Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.5017

Authors: Johann S. De Bono, Ugo De Giorgi, Christophe Massard, Sergio Bracarda, Ivo Kocak, Albert Font, Jose Angel Arranz Arija, Kent C. Shih, George Daniel Radavoi, Wei Yu, Wai Y. Chan, Jian Huang, Luna C. Musib, Steven Gendreau, Raymond D. Meng, Premal H Patel, Daniel J. Maslyar, Viorel Jinga

Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Institut Gustave Roussy, Ospedale San Donato, Masaryk Memorial Cancer Institute, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Hospital General Universitario Gregorio Marañón, Tennessee Oncology, Carol Davila University of Medicine and Pharmacy, Genentech

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2763817278

Cites:

Cited by: 18

Related to: 10